NCT00414999View on ClinicalTrials.gov

A Phase 1 Safety Study of TG100801 Eye Drops in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

November 30, 2006

Study Completion Date

February 28, 2007

Conditions
Macular DegenerationDiabetic Retinopathy
Interventions
DRUG

TG100801

Trial Locations (1)

66219

Quintiles Phase One Services, Inc., Lenexa

Sponsors

Lead Sponsor

TargeGen
All Listed Sponsors
lead

TargeGen

INDUSTRY